S3-Leitlinie Empfehlungen zur Therapie von Patienten mit COVID-19 AWMF Register Nummer 113-001LG

Published by Nina Kreuzberger, Nicole Skoetz, Stefan Kluge on Sep 25, 2024

View

Disclaimer

Sponsors

Contact

Abstract

Language

de

PICOS

PICO 10.1

Population
Outpatients with confirmed SARS-CoV-2 infection (at high risk of disease progression)
Intervention
Nirmatrelvir / ritonavir plus standard of care
Comparator
Placebo plus standard of care
Outcomes

PICO 10.1

Population
Individuals with COVID-19 and ARDS
Intervention
Prone positioning (> 5 hours)
Comparator
Any position
Outcomes

PICO 10.1

Population
All adult patients (with or without risk factors for COVID-19) with positive PCR test for SARS-CoV-2
Intervention
inhaled corticosteroid
Comparator
placebo and/or standard of care
Outcomes

PICO 10.1

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
Systemic corticosteroids + Standard of care
Comparator
Standard of Care (plus/minus Placebo)
Outcomes

PICO 10.2

Population
Hospitalised patients
Intervention
Paxlovid plus standard of care
Comparator
Standard of care alone
Outcomes

PICO 10.2

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
High-dose dexamethasone (12 mg or higher)
Comparator
Low-dose dexamethasone (6-8 mg)
Outcomes

PICO 10.3

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
Weight-based dexamethasone (0.2 mg/kg)
Comparator
Low-dose dexamethasone (6-8 mg)
Outcomes

PICO 20.1

Population
Ambulatory managed individuals with a confirmed diagnosis of SARS-CoV-2 infection and mild disease, according to the WHO clinical progression scale (WHO 2 to 3)
Intervention
Remdesivir + Standard of Care
Comparator
Standard of Care (with or without placebo)
Outcomes

PICO 20.1

Population
Hospitalised patients with confirmed SARS-CoV-2 infection and with moderate to severe disease, according to the WHO clinical progression scale (WHO 4 to 9)
Intervention
Intermediate dose anticoagulation
Comparator
Standard thromboprophylaxis (low dose)
Outcomes

PICO 20.1

Population
Ambulatory managed individuals with a confirmed diagnosis of SARS-CoV-2 infection and mild disease, according to the WHO clinical progression scale (WHO 2 to 3)
Intervention
Standard thromboprophylaxis (low dose)
Comparator
No anticoagulation (placebo/SoC)
Outcomes

PICO 20.1

Population
Outpatients with confirmed COVID-19 diagnosis
Intervention
Evushield plus standard of care
Comparator
Placebo plus standard of care
Outcomes

PICO 20.1

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
Tocilizumab + Standard of Care
Comparator
Standard of Care (plus/minus Placebo)
Outcomes

PICO 20.2

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
Remdesivir + Standard of Care
Comparator
Standard of Care (with or without placebo)
Outcomes

PICO 20.2

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
Evushield plus standard of care
Comparator
Placebo plus standard of care
Outcomes

PICO 20.2

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
High-dose tocilizumab (8 mg/kg)
Comparator
Low-dose tocilizumab (4 mg/kg)
Outcomes

PICO 20.2

Population
Ambulatory managed individuals with a confirmed diagnosis of SARS-CoV-2 infection and mild disease, according to the WHO clinical progression scale (WHO 2 to 3)
Intervention
Therapeutic dose anticoagulation
Comparator
No anticoagulation (placebo/SoC)
Outcomes

PICO 20.2

Population
Hospitalised patients with confirmed SARS-CoV-2 infection and with moderate to severe disease, according to the WHO clinical progression scale (WHO 4 to 9)
Intervention
Therapeutic dose anticoagulation
Comparator
Standard thromboprophylaxis (low dose/intermediate dose))
Outcomes

PICO 20.3

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
Sotrovimab, 500 mg plus standard of care
Comparator
Placebo plus standard of care
Outcomes

PICO 20.3

Population
Ambulatory managed individuals with a confirmed diagnosis of SARS-CoV-2 infection and mild disease, according to the WHO clinical progression scale (WHO 2 to 3)
Intervention
Therapeutic dose anticoagulation
Comparator
Standard thromboprophylaxis (low dose)
Outcomes

PICO 20.4

Population
Outpatients with confirmed SARS-CoV-2 infection (and at least one risk factor for severe disease)
Intervention
Sotrovimab plus standard of care
Comparator
Placebo plus standard of care
Outcomes

PICO 30.1

Population
Immunocompromised with persistent SARS-CoV-2 infection
Intervention
Combination therapy
Comparator
No therapy
Outcomes

PICO 40.1

Population
Anakinra for the treatment of COVID-19
Intervention
Anakinra
Comparator
standard care with or without placebo or no treatment
Outcomes

PICO 40.1

Population
Post-discharge COVID-19 patients
Intervention
Standard thromboprophylaxis (low dose)
Comparator
No anticoagulation (placebo/SoC)
Outcomes